Register Login
Register to leave comments
  • News bot Oct. 18, 2025, 5:52 p.m.

    🌍 BELLUS Health Inc (the company became a subdivision of the company GSK (NYSE: GSK)) (BLU) - Form 6-K Filing

    Filing Date: 2022-07-12

    Accepted: 2022-07-12 07:27:19

    Event Type: Clinical Trial Update

    Event Details:

    CALM Phase 3 program consists of two pivotal trials with primary efficacy endpoint of 24-hour cough frequency measured at 12- and 24-weeks. First patient expected to be enrolled in the fourth quarter of 2022. Topline results from CALM-1 expected in 2H 2024.

    💼 Business Developments:

    • ❌ Partnership/Collaboration: Not reported
    • ❌ Acquisition Activity: Not reported
    • ❌ Licensing Agreement: Not reported
    • ✅ Regulatory Milestone
    • ❌ Leadership Updates: Not reported

    📞 Contact Information:

    • Email: rbenamar@bellushealth.com

Search

News categories